Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Dose-Escalation Study of Oral ARRY-438162 in Patients With Advanced Solid Tumors Followed by an Expansion Cohort in Patients With Advanced or Metastatic Biliary Cancer

Trial Profile

A Phase 1 Dose-Escalation Study of Oral ARRY-438162 in Patients With Advanced Solid Tumors Followed by an Expansion Cohort in Patients With Advanced or Metastatic Biliary Cancer

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 09 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Binimetinib (Primary)
  • Indications Adenocarcinoma; Biliary cancer; Colorectal cancer; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Array BioPharma
  • Most Recent Events

    • 22 May 2018 Results (n=28) assessing the tolerability, pharmacokinetics, and pharmacodynamics of ARRY 162 in patients with advanced solid tumours, followed by expansion cohorts in patients with advanced or metastatic biliary cancer and in patients with KRAS-mutant and BRAF-mutant colorectal cancer, were published in the Investigational New Drugs.
    • 02 Feb 2017 Results published in the British Journal of Cancer
    • 01 Jan 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top